MPLT Overview

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients suffering from debilitating central nervous system disorders (CNS). Its lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist, ML-007, co-formulated with a peripherally acting anticholinergic (PAC), which it is initially developing for the treatment of schizophrenia and Alzheimer’s disease psychosis (ADP). ML-007C-MA is designed to activate both M1 and M4 muscarinic receptors in the CNS to drive efficacy, while synchronizing the pharmacokinetics of the agonist and antagonist components to mitigate peripheral cholinergic side effects. Its second product candidate, ML-004, is a 5-HT1B/1D agonist that the Company is developing for the treatment of social communication deficit and/or irritability in autism spectrum disorder. It is also advancing two preclinical programs, ML-021 and ML-009.

Wall Street analysts forecast MPLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MPLT is31.00 USD with a low forecast of 28.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

MapLight Therapeutics Inc revenue for the last quarter amounts to -19.98M USD, decreased

MapLight Therapeutics Inc. EPS for the last quarter amounts to -17820000.00 USD, decreased

MapLight Therapeutics Inc (MPLT) has 0 emplpoyees as of March 17 2026.

Today MPLT has the market capitalization of 857.10M USD.